JP2013511526A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511526A5
JP2013511526A5 JP2012539987A JP2012539987A JP2013511526A5 JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5 JP 2012539987 A JP2012539987 A JP 2012539987A JP 2012539987 A JP2012539987 A JP 2012539987A JP 2013511526 A5 JP2013511526 A5 JP 2013511526A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
agent
substituted
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012539987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013511526A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056942 external-priority patent/WO2011062939A1/en
Publication of JP2013511526A publication Critical patent/JP2013511526A/ja
Publication of JP2013511526A5 publication Critical patent/JP2013511526A5/ja
Ceased legal-status Critical Current

Links

JP2012539987A 2009-11-18 2010-11-17 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物 Ceased JP2013511526A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US61/262,342 2009-11-18
US29203210P 2010-01-04 2010-01-04
US61/292,032 2010-01-04
PCT/US2010/056942 WO2011062939A1 (en) 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies

Publications (2)

Publication Number Publication Date
JP2013511526A JP2013511526A (ja) 2013-04-04
JP2013511526A5 true JP2013511526A5 (enExample) 2015-06-11

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539987A Ceased JP2013511526A (ja) 2009-11-18 2010-11-17 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物

Country Status (18)

Country Link
US (2) US20120232087A1 (enExample)
EP (1) EP2501370A1 (enExample)
JP (1) JP2013511526A (enExample)
KR (1) KR20120107962A (enExample)
CN (2) CN104224791A (enExample)
AU (1) AU2010322114B2 (enExample)
BR (1) BR112012011823A2 (enExample)
CA (1) CA2781210A1 (enExample)
CL (1) CL2012001271A1 (enExample)
IL (1) IL219636A0 (enExample)
MA (1) MA33739B1 (enExample)
MX (1) MX2012005695A (enExample)
NZ (1) NZ599964A (enExample)
PH (1) PH12012500911A1 (enExample)
RU (1) RU2012125152A (enExample)
TN (1) TN2012000205A1 (enExample)
WO (1) WO2011062939A1 (enExample)
ZA (1) ZA201203325B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012125070A (ru) 2009-11-18 2013-12-27 Плексксикон, Инк. Соединения и способы модулирования киназы и показания к их применению
WO2012166241A1 (en) * 2011-06-02 2012-12-06 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
US9499539B2 (en) * 2012-11-05 2016-11-22 Nantbioscience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
IL302385B2 (en) 2017-01-06 2024-06-01 Palvella Therapeutics Inc Non-aqueous preparations of mTOR inhibitors and methods of use
LT3786160T (lt) 2017-10-27 2022-09-26 Boehringer Ingelheim International Gmbh Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク. mTOR阻害剤の無水組成物および使用方法
WO2020061584A1 (en) * 2018-09-21 2020-03-26 Msb Holdings, Inc. Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
EP1954699B1 (en) 2005-11-22 2012-09-19 Kudos Pharmaceuticals Ltd PYRIDO-, PYRAZO- AND PYRIMIDOPYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
RS55881B1 (sr) 2006-08-23 2017-08-31 Kudos Pharm Ltd 2-metilmorfolin pirido-,pirazo- i pirimido-pirimidin derivati kao inhibitori mtor-a
BRPI0809193A2 (pt) * 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
EP2249844A1 (en) * 2008-03-12 2010-11-17 Ludwig-Maximilians-Universität München Active substance combination with gemcitabine for the treatment of epithelial cancer
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Similar Documents

Publication Publication Date Title
JP2013511526A5 (enExample)
ES2609767T3 (es) Combinaciones de un inhibidor de PI3K y un inhibidor de MEK
Nonnenmacher et al. RIST: A potent new combination therapy for glioblastoma
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP6648040B2 (ja) がん治療のための併用療法としてのエリブリン及びポリ(adpリボース)ポリメラーゼ(parp)阻害剤の使用
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
AU2015289504B2 (en) Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
ES2861180T3 (es) Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etan-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
JP2011529474A (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
JP2022145800A (ja) 静止細胞標的化およびegfr阻害剤を用いた新生物の処置のための組み合わせ
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
JP2018510869A (ja) 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリンを含んでいる組合せ
Mazzoletti et al. PI3K/AKT/mTOR inhibitors in ovarian cancer
AU2013341271A1 (en) Combination therapy
JP2020523354A5 (enExample)
JP5440985B2 (ja) メラノーマの治療
JP2013511526A (ja) 固形腫瘍及びその他の悪性腫瘍を治療するための方法及び組成物
CA3253034A1 (en) METHODS FOR TREATMENT OF MYELOID MALIGNITIS USING A BCL-2 INHIBITOR
ES2685974T3 (es) Derivados de cefalosporina para tratar el cáncer
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
ITMI20042475A1 (it) Uso di derivati tiazolidinonici come agenti terapeutici
MX2023011814A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o la mejora del cancer.
Kasper et al. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge?
RU2012123970A (ru) Тивозаниб и темсиролимус в комбинации
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合